胃肠病科和肝病科

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Symptoms During a Gastric Emptying Study

   Rochester, Minn.

   To understand the utility of measuring stomach emptying, symptoms during a stomach emptying, and blood markers of body metabolism.

2. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint

   Jacksonville, Fla.

   The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis.

3. Evaluating Markers which Might be a Predictor of Pancreatic Cancer or Precancer by Analyzing the Secretions (fluid) from a Pancreatic cyst

   Rochester, Minn.

   The purpose of this study is to evaluate molecular markers which might be a predictor of pancreatic cancer or precancer by analyzing the secretions (fluid) from a pancreatic cyst, pancreas fluid and tissue from a resected pancreatic cyst.

4. Detection of Plasma DNA Methylation in Peripheral Blood from Patients with Hepatocellular Carcinoma

   Rochester, Minn.

   This study aims to investigate the utility of using plasma DNA methylation to detect measurable residual disease or early recurrence/progression of patients with hepatocellular carcinoma.

5. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls

   Jacksonville, Fla.

   The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes.

6. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.

7. A Study to Assess Clonal Diversity of Freshly Taken ESD Specimens

   Rochester, Minn.

   Inclusion Criteria:

   • Patients with Barrett’s Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment.

   Exclusion Criteria: 

   • Patients without BE or EAC or that are not planned for ESD treatment.

8. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to develop a biorepository of blood samples  from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. 

9. Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

   Rochester, Minn.

   The purpose of this study is to compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

10. Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

    Rochester, Minn., Mankato, Minn., La Crosse, Wis., Jacksonville, Fla., Eau Claire, Wis., Austin, Minn., Scottsdale/Phoenix, Ariz.

    This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.